Public biotech in 2017-the numbers.
| Products/Services Used |
Details |
Operation |
| CRISPR Cell Line Engineering |
Newcomers and bellwethers At the end of 2017, there were 30 large-cap biotechs (companies with market capitaliza- tion of >$5 billion), up from 24 at the end Table 3 Top ten partnership and licensing deals by upfront cash in 2017 Company (role) Bayer (licensee) Loxo Oncology (licensor) GenScript Biotech (licensor) Johnson & Johnson (licensee) Biogen (licensee) Bristol-Myers Squibb (licensor) Celgene (licensee) BeiGene (licensor) Merck KGaA (licensee) Vertex Pharmaceuticals (licensor) Incyte (licensee) MacroGenics (licensor) Eli Lilly (licensee) Nektar Therapeutics (licensor) Dermira (licensee) Genentech (licensor) Roche (Other) Bristol-Myers Squibb (BMS, licensee) Halozyme Therapeutics (licensor) Allergan (licensee) Editas Medicine (licensor) Source: BioCentury BCIQ Deal headline Loxo Oncology grants Bayer worldwide rights to develop and commercialize inhibitors of the Trk family of receptor tyrosine kinases larotrectinib (LOXO-101) and LOXO-195 to treat cancer J&J’s Janssen Biotech unit partners with GenScript Biotech’s Legend Biotech subsidiary to jointly develop and commercialize Legend’s CAR-T-targeting BCMA (LCAR-B38M) to treat multiple myeloma (MM) worldwide Bristol-Myers Squibb grants Biogen exclusive, worldwide rights to develop and commercialize anti-tau mAb (BMS-986168)to treat progressive supranuclear palsy and Alzheimer’s disease BeiGene grants Celgene exclusive, worldwide rights, excluding Asia, but including Japan, to anti-PD-1 mAb (BGB-A317) to treat non-hematological indications and also purchases Celgene’s commercial operations in China Vertex Pharmaceuticals granted Merck exclusive, worldwide rights to four cancer programs MacroGenics grants Incyte exclusive, worldwide rights to develop and commercialize IgG4 mAb against PD-1 (MGA012) to treat solid tumors Nektar Therapeutics partners with Eli Lilly to co-develop Nektar’s interleukin (Il)-2-targeting cytokine (NKTR-358) to treat autoimmune diseases Roche’s Genentech grants Dermira exclusive, worldwide rights to develop and commercialize IgG4 mAb against Il-13 (lebrikizumab) for all indications except interstitial lung diseases Date announced 14-Nov Upfront cash ($ millions) 400 21-Dec 350 13-Apr 300 5-Jul 263 11-Jan 230 25-Oct 150 24-Jul 8-Aug 150 135 Halozyme Therapeutics grants BMS rights to use its Enhanze (hyaluronidase) drug delivery tech - nology to develop subcutaneous versions of immuno-oncology products against up to 11 targets Editas Medicine grants Allergan an exclusive option to license up to five of Editas’ CRISPR–Cas ocular programs 14-Sep 105 14-Mar 90 5 7 8 VO LUM E 36 NUMB ER 7 JU LY 2018 NATUR E B IOT ECHNO LOGY of 2016 (Fig.... Johnson & Johnson entered the CAR-T fray via a December deal for an autologous multiple myeloma treatment tar- geting BCMA with Legend Biotech (Nanjing, China), a subsidiary of Genscript Biotech worth $350 million upfront. |
Get A Quote |
